• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Biolex Therapeutics

edit

Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Milestones

edit

• 
  Biolex Therapeutics added Jan Turek as President and CEO.
  Posted 6/22/09 at 11:58am
• 
  Biolex Therapeutics received $20M in Series D funding. (10/29/10)
  Posted 10/29/10 at 5:57pm via dowjones.com
• 
  Biolex Therapeutics received $8M in Unattributed funding. (1/7/05)
  Posted 7/4/10 at 11:30pm
• 
  Biolex Therapeutics received $36M in Series B funding. (9/1/05)
  Posted 7/1/10 at 5:17am via biolex.com
• 
  Biolex Therapeutics received $30M in Series C funding. (5/24/07)
  Posted 3/11/10 at 11:29pm via biolex.com
• 
  Biolex Therapeutics received $60M in Series D funding. (10/6/08)
  Posted 6/22/09 at 11:58am via mitsuiventures.com

Videos

Screenshots

edit

Above: Biolex Therapeutics Screenshot -- #1
Uploaded: 6/22/09

Sources

1. Cap Funding Report [edit]
2. BIOLEX THERAPEUTICS RAISES $36 MILLION IN VENTURE FINANCING (biolex.com) [edit]
3. BIOLEX THERAPEUTICS RAISES $30 MILLION TO ADVANCE ITS HEPATITIS C DRUG CANDIDATE AND OTHER PIPELINE PROGRAMS (biolex.com) [edit]
4. Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C (mitsuiventures.com) [edit]
5. Biolex Gets $20M From Insiders, Sees Strong Data From Hepatitis C Drug (fis.dowjones.com) [edit]